5 billion people have access to medicine 2 billion to go


The Access to Medicine Foundation stimulates and guides pharmaceutical companies to do more for the people living in low- and middle-income countries without access to medicine.

Who we are
What we analyse
How we drive change

The Index finds a high level of diversity in how vaccine companies are improving access to vaccines for people living in poorer countries. GSK leads the three areas evaluated, with a strong performance from Sanofi across the board

News and Events

The Access to Medicine Foundation has moved!

21 Apr 2017
The Access to Medicine Foundation has outgrown its former office in Haarlem and moved to a larger space in Amsterdam. The new office is close to the Amsterdam Sloterdijk station on Naritaweg 227-A, 1043 CB, Amsterdam.

Out now: the first Access to Vaccines Index

06 Mar 2017
The first Access to Vaccines Index will be published on Monday 6 March, 2017. It is the first tool of its kind to present the current landscape of vaccine company behaviour when it comes to making vaccines more accessible for the populations that need them.

Foundation to track pharma company progress on AMR

13 Dec 2016
The Access to Medicine Foundation has started work on a new tool – an Antimicrobial Resistance Benchmark that will track how pharmaceutical companies are responding to the increase in drug-resistance. The AMR Benchmark is currently funded by the UK and Dutch governments.

New analysis: large pharmaceutical companies are developing five HIV/AIDS medicines for children

29 Nov 2016
For World AIDS Day 2016, the Access to Medicine Foundation has analysed the pharmaceutical pipelines for HIV/AIDS from 20 of the world’s largest pharmaceutical companies. Out of 51 high-burden diseases and conditions, HIV/AIDS is one of the five diseases getting the most R&D attention. Today, they have five projects in the pipeline aimed at children.

AMR and Access to Cancer Medicine, discussing the role of the pharma industry

20 Sep 2016
Jayasree K. Iyer will participate in two key events on the role of the pharmaceutical industry regarding access to antimicrobials and AMR, and in improving access to cancer medication. She will speak at the UN General Assembly side event on AMR; and at the Royal Society of Medicine on access to cancer medicine.
Access to Medicine Index Cover

Access to Medicine Index 2016

The only in-depth comparison of the world’s largest pharma companies on how they improve access to medicine for the poor.

Visit website

Access to Vaccines Index Cover

Access to Vaccines Index 2017

The first tool to show how vaccine companies are responding to calls to increase access to vaccines.

Visit website

Join our team

Positions in Research, AMR, Communications
Interested in working toward the next Access to Medicine Index or our new AMR Benchmark? Or in joining the Foundation’s Communications team?


Access to medicine: a material issue for investors
Investors engage with the Foundation for insight into our analysis of the pharma sector, including into governance structures, R&D and pricing strategies.

The foundation on Twitter

Access to Medicine's Twitter avatar
Access to Medicine

In their campaign encouraging #vaccine #access for every last child @GlblCtznImpact features a synopsis of #ATVI2017 t.co/Q7LSqscUP6

Access to Medicine's Twitter avatar
Access to Medicine

.@GlblCtznImpact features a synopsis of The Access to Vaccines Index 2017 @gavi @UNICEF t.co/VxgnTcnVlH

Access to Medicine's Twitter avatar
Access to Medicine

Vaccine producers & manufacturers key in ensuring #vaccine #access. #ATVI2017 maps actions by industry… t.co/DKzBh0eLmG

Access to Medicine's Twitter avatar
Access to Medicine

Millions of people need better access to #vaccines. How are vaccine companies responding? #WorldImmunizationWeekt.co/V0b9WlFxcf

Access to Medicine's Twitter avatar
Access to Medicine

What can we learn about #access from the world’s first #malaria #vaccine? #ATVI2017 analysis reveals...#access2meds… t.co/TxeJlzrU6T

Encourage pharma companies Access to Medicine


Incentivising pharma to develop medicine for the poor
Which mechanisms work for engaging pharma companies in R&D for diseases of poverty?

“To improve access, we believe pharmaceutical companies need to focus on how
they deploy their products, and, as global citizens, collaborate on the development of strong health systems.”

Jayasree K. Iyer, Executive Director, Access to Medicine Foundation.


Embedding pro-access governance


Mainstreaming inclusive business models


Improving industry responsiveness to public health priorities


Employing ‘access-thinking’ in product deployment


Addressing unmet needs through R&D

The Access to Medicine Foundation and its publications are funded by